Document:

Document

Exhibit 10.6

AMENDMENT 
TO 
ALNYLAM PHARMACEUTICALS, INC. 
AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN 
C. The Alnylam Pharmaceuticals, Inc. Amended and Restated 2004 Employee Stock Purchase Plan (as amended, the “Plan”) is hereby amended by the Board of Directors of Alnylam Pharmaceuticals, Inc. (the “Company”), subject to approval of the Company’s stockholders, to, among other things, increase the aggregate number of shares authorized for issuance under the Plan by 750,000 shares of common stock, par value $0.01 per share, of the Company: 
1. The second sentence of the second paragraph of the Plan is hereby amended and restated in its entirety as follows: 
“An aggregate of 1,965,789 shares of Common Stock have been approved for this Plan.” 
D. Except as amended herein, the Plan is confirmed in all other respects. 
Approved by the Board of Directors on March 1, 2020.kura-ex104_31.htm

 

Exhibit 10.4

 

Amended and Restated Non-Employee Director Compensation Policy

 

Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Kura Oncology, Inc. (“Kura”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service. This Policy is effective as of March 12, 2020 for the Lead Independent Director Service Retainer and as of January 1, 2020 for all other service retainers (the “Effective Date”) and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

 

Annual Cash Compensation

 

The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. 

 

	
1.
	
Annual Board Service Retainer: 

a.All Eligible Directors: $40,000

 

	
2.
	
Annual Committee Member Service Retainer:

a.Member of the Audit Committee: $7,500

b.Member of the Compensation Committee: $5,000

c.Member of the Nominating & Governance Committee: $4,000

 

	
3.
	
Annual Committee Chair Service Retainer (in addition to Committee Member Service Retainer):

a.Chairman of the Audit Committee: $7,500

b.Chairman of the Compensation Committee: $5,000

c.Chairman of the Nominating & Governance Committee: $4,000

 

	
4.
	
Annual Lead Independent Director Service Retainer: $27,500

 

Equity Compensation

 

The equity compensation set forth below will be granted under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (the “Plan”). All stock options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock of Kura on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service 

 

 

other than for death, disability or cause, the post-termination exercise period will be 12 months from the date of termination).

 

1.Initial Grant: On the date of the Eligible Director’s initial election to the Board, for each Eligible Director who is first elected to the Board on or following the Effective Date (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 46,000 shares (the “Initial Grant”).  The shares subject to each Initial Grant will vest in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

 

2.Annual Grant: On the date of each Kura’s annual stockholder meeting held after the Effective Date, for each Eligible Director who continues to serve as a non-employee member of the Board (or who is first elected to the Board at such annual stockholder meeting), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 23,000 shares (the “Annual Grant”). In addition, each Eligible Director who is first elected to the Board following (i) the Effective Date and (ii) the date of Kura’s first annual stockholder meeting, and other than at an annual stockholder meeting will be automatically, and without further action by the Board or Compensation Committee of the Board, granted an Annual Grant, pro-rated for the number of months remaining until the next annual stockholder meeting.  The shares subject to the Annual Grant will vest on the one year anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

 

2xene-ex102_140.htm

 

Exhibit 10.2

 

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [†].

AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT

This Amendment No. 1 (this “Amendment”), dated August 4, 2020 (the “Effective Date”), modifies that certain Asset Purchase Agreement (the “Agreement”) entered into as of April 25, 2017 by and between 1ST Order Pharmaceuticals, Inc., a Delaware Corporation (“Seller”) and Xenon Pharmaceuticals Inc., a corporation continued under the federal laws of Canada (“Acquiror”).

WHEREAS, Seller and Acquiror wish to amend certain language in the Agreement with respect to Milestones 1 and 8; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 

	
1.
	
Definitions. For all purposes of and under this Amendment and the Agreement the capitalized terms shall have the meanings set forth below. Any capitalized terms not defined herein shall have the meanings set forth in the Agreement. 

	
 
	
1.1. 
	
“[†]” means [†]. 

	
 
	
1.2. 
	
“[†]” means [†]. 

	
2.
	
Milestone Payments. Section 2.4(a) of the Agreement is hereby deleted in its entirety and replaced with the following: 

	
 
	
(a)
	
Subject to the terms and conditions of this Agreement, the Seller shall be entitled to certain milestone payments (each payment as it relates to a particular event, a “Milestone Payment”), each of which, if achieved, will be due and payable within [†] following achievement of the applicable event set forth below for the first Product to achieve such event (each, a “Milestone Event”); provided, however, that no Milestone Payments will be earned or payable to Seller if an applicable event set forth below is achieved on or after the [†] anniversary of the Closing Date:

 

 

			
			
	
Milestone Event Number
	
Milestone Event
	
Milestone Payment

	
 
	
Patent Milestone Event
	
 

	
1.
	
 
	
 

	
1(a)
	
Execution of Amendment No. 1
	
$0.3M

	
1(b)
	
[†]
	
[†]

	
1(c)
	
[†]
	
[†]

	
1(d)

 
	
[†]
	
[†]

	
 
	
Regulatory Milestone Event
	
 

	
2.
	
[†]
	
[†]

	
3.
	
[†]
	
[†]

	
4.
	
[†]
	
[†]

	
5.
	
[†]
	
[†]

	
6.
	
[†]
	
[†]

	
7.
	
[†]
	
[†]

For purposes of clarity, (i) Milestone Event Number 1(c) is in addition to, and not a replacement for, Milestone Event Number 4, making the total amount payable [†], depending on the outcome of Milestone Event Number 1(b). 

	
3.
	
[†]. Subject to confidentiality and privacy obligations and applicable law, Acquiror agrees to provide Seller with periodic updates on the progress made on achieving the [†] as well as with the first draft of the clinical study report (including all Tables, Listings, and Figures [TLFs]). [†].

	
4.
	
Mutual Release by All Parties. Each party hereby does and shall, for itself and its successors, predecessors, parents, subsidiaries, stockholders, past and current employees, officers, trustees, directors, board members, representatives, agents, and assigns in their official and individual capacities (collectively, the “Releasing Parties”), release the other party and its successors, predecessors, parents, subsidiaries, partnerships, associated and affiliated companies, related entities, past and current officers, trustees, directors, members, board members, employees, agents, attorneys, insurance companies, and assigns in their official and individual capacities (collectively, the “Released Parties”) from any and all claims, actions, causes of action, grievances, suits, charges, or complaints of any kind or nature whatsoever, that the Releasing Parties ever had or now have up to the Effective Date, arising from or relating to the payment of certain Milestone Payments, including any payment or non-payment thereof, whether fixed or contingent, liquidated or unliquidated, known or unknown, suspected or unsuspected, and whether arising in tort, contract, statute, or equity, before any federal, state, administrative, local, or private court, agency, arbitrator, mediator, or other entity, regardless of the relief or remedy.  The Releasing Parties acknowledge and agree that they are aware that statutes exist that render null and void releases of any claims, rights, demands, liabilities, actions and causes of action which are unknown to the Releasing Parties at the time of execution of the release. The Releasing Parties expressly waive, surrender and agree to forego any protection to which they otherwise would be entitled against one another by virtue of the existence of any such statute in any jurisdiction. The Releasing Parties each retain the rights and remedies expressly or impliedly provided to the Releasing Parties by the original terms of the Agreement which are not amended in this Amendment.

	
5.
	
Agreement. Except as specifically amended by this Amendment No. 1, the Agreement shall remain in full force and effect. 

 

 

In witness whereof, the Parties have executed this Amendment No. 1 as of the Effective Date.

					
	
1ST ORDER PHARMACEUTICALS, INC.
	
 
	
XENON PHARMACEUTICALS INC.

	
By:
	
/s/ Christopher Crean
	
 
	
By:
	
/s/ Simon Pimstone

	
Name:
	
Christopher Crean
	
 
	
Name:
	
Simon Pimstone

	
Title
	
President CSO
	
 
	
Title:
	
CEO

 

 

 

 

 

EXHIBIT A

[†]

[†]

1.  [†]

2.  [†]

3.  [†]

4.  [†]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]